These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 17627250)

  • 1. Is low-dose valganciclovir the same as appropriate-dose valganciclovir?
    Pescovitz MD
    Transplantation; 2007 Jul; 84(1):126; author reply 126-7. PubMed ID: 17627250
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants.
    Weng FL; Patel AM; Wanchoo R; Brahmbhatt Y; Ribeiro K; Uknis ME; Mulgaonkar S; Mathis AS
    Transplantation; 2007 Feb; 83(3):290-6. PubMed ID: 17297403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
    J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose valganciclovir for cytomegalovirus prophylaxis in organ transplantation: is less really more?
    Avery RK
    Clin Infect Dis; 2011 Feb; 52(3):322-4. PubMed ID: 21190935
    [No Abstract]   [Full Text] [Related]  

  • 5. What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation?
    Lamoth F; Manuel O; Venetz JP; Faouzi M; Meylan P; Pascual M
    Transplantation; 2008 Nov; 86(9):1323-4. PubMed ID: 19005418
    [No Abstract]   [Full Text] [Related]  

  • 6. Cytomegalovirus prophylaxis using oral ganciclovir or valganciclovir in kidney and pancreas-kidney transplantation under antibody preconditioning.
    Keven K; Basu A; Tan HP; Thai N; Khan A; Marcos A; Starzl TE; Shapiro R
    Transplant Proc; 2004 Dec; 36(10):3107-12. PubMed ID: 15686707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation.
    Kalpoe JS; Schippers EF; Eling Y; Sijpkens YW; de Fijter JW; Kroes AC
    Antivir Ther; 2005; 10(1):119-23. PubMed ID: 15751769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regarding: Humar et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010;10:1228–1237.
    da Cunha-Bang C; Iversen M; Mortensen SA; Rasmussen A; Sengeløv H; Sørensen SS; Lundgren J
    Am J Transplant; 2011 Feb; 11(2):408. PubMed ID: 21219564
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy of valganciclovir plus cytomegalovirus immune globulin for prevention of cytomegalovirus disease in high-risk renal transplant recipients.
    Maldonado AQ; Bitterman AN; Ojogho ON; Bowen KA; Weeks DL
    Ann Pharmacother; 2014 Apr; 48(4):548-9. PubMed ID: 24658636
    [No Abstract]   [Full Text] [Related]  

  • 10. Valganciclovir versus IV ganciclovir for therapy of cytomegalovirus viremia: has victory been achieved?
    Avery RK
    Am J Transplant; 2007 Sep; 7(9):2062-3. PubMed ID: 17697259
    [No Abstract]   [Full Text] [Related]  

  • 11. A prospective assessment of valganciclovir for the treatment of cytomegalovirus infection and disease in transplant recipients.
    Humar A; Siegal D; Moussa G; Kumar D
    J Infect Dis; 2005 Oct; 192(7):1154-7. PubMed ID: 16136456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of pre-emptive or prophylactic valganciclovir therapy for prevention of cytomegalovirus infection in renal transplantation.
    Santos RD; Brennan DC
    J Am Soc Nephrol; 2012 Sep; 23(9):1446-8. PubMed ID: 22878958
    [No Abstract]   [Full Text] [Related]  

  • 13. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir.
    Mattes FM; Hainsworth EG; Hassan-Walker AF; Burroughs AK; Sweny P; Griffiths PD; Emery VC
    J Infect Dis; 2005 Jan; 191(1):89-92. PubMed ID: 15593008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower-dose valganciclovir for the prevention of cytomegalovirus after solid organ transplantation: an important tradeoff.
    Arasaratnam RJ
    Transpl Infect Dis; 2015 Aug; 17(4):623-4. PubMed ID: 25919304
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial commentary: Use of valganciclovir for prevention and treatment of cytomegalovirus disease.
    Snydman DR
    Clin Infect Dis; 2008 Jan; 46(1):28-9. PubMed ID: 18171209
    [No Abstract]   [Full Text] [Related]  

  • 16. Response to: lower-dose valganciclovir for prevention of cytomegalovirus after solid organ transplant: an important tradeoff.
    Stevens DR; Sawinski D; Blumberg E; Bloom RD; Trofe-Clark J
    Transpl Infect Dis; 2015 Aug; 17(4):625-6. PubMed ID: 25919221
    [No Abstract]   [Full Text] [Related]  

  • 17. Why valganciclovir should not be indicated for liver recipients and high-dose acyclovir should not be removed from international cytomegalovirus guidelines.
    Kalil AC; Florescu DF
    Transplantation; 2011 Jan; 91(1):e8-9; author reply e10. PubMed ID: 21441850
    [No Abstract]   [Full Text] [Related]  

  • 18. Cytomegalovirus ulcer. Successful treatment with valganciclovir.
    Lambert EM; Strasswimmer J; Lazova R; Antaya RJ
    Arch Dermatol; 2004 Oct; 140(10):1199-201. PubMed ID: 15492181
    [No Abstract]   [Full Text] [Related]  

  • 19. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation.
    Ciancio G; Burke GW; Mattiazzi A; Leibovici Z; Dowdy L; Roth D; Kupin W; Rosen A; Jorge D; Cirocco RE; Miller J
    Clin Transplant; 2004 Aug; 18(4):402-6. PubMed ID: 15233817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
    van der Heiden PL; Kalpoe JS; Barge RM; Willemze R; Kroes AC; Schippers EF
    Bone Marrow Transplant; 2006 Apr; 37(7):693-8. PubMed ID: 16501590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.